Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431822 | 0.93 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL1432001 | 0.90 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL1432199 | 0.90 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL1431554 | 0.90 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL1431890 | 0.90 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL1432059 | 0.89 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL1432062 | 0.89 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL1431413 | 0.87 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL1431757 | 0.86 | CNR1 (0.50) | CNR1CNR2 | |
| SCHEMBL1431731 | 0.85 | CNR2 (0.61) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923465-B2 | CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-04-12 | — | — | US | claimed |
| EP-1902034-B1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2011-03-30 | — | — | EP | claimed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | claimed |
| EP-1902034-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | Glenmark Pharmaceuticals S.A. (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006129178-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-12-07 | — | — | WO | claimed |
| US-8420689-B2 | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-07 | — | — | US | disclosed |
| US-7923465-B2 | CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-04-12 | — | — | US | disclosed |
| EP-1902034-B1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| EP-1902034-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | Glenmark Pharmaceuticals S.A. (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006129178-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885 |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | CNR2, CNR1, OPRL1 | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.